Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
11:15am, Wednesday, 13'th Aug 2025
Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 cl
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
08:30am, Monday, 04'th Aug 2025
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
08:30am, Monday, 21'st Jul 2025
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 18'th Jul 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
08:30am, Thursday, 17'th Jul 2025
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
04:00pm, Thursday, 10'th Jul 2025
CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of�
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 01'st Jul 2025
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market
02:31pm, Monday, 30'th Jun 2025
H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept.
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
11:41am, Monday, 30'th Jun 2025
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Vor Bio Announces $175 Million Private Placement
04:50pm, Wednesday, 25'th Jun 2025
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
04:45pm, Wednesday, 25'th Jun 2025
-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -Re
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
08:30am, Thursday, 08'th May 2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from it
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
04:05pm, Thursday, 20'th Mar 2025
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment Sys
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinica
